Bluebird bio Inc BLUE 2.51% and Celgene Corporation CELG 0.18% announced a restructuring of its CAR-T collaboration this week. Under the amended terms of the deal, the collaboration will focus on CAR-T cells that target the B-cell maturation antigen (BCMA). Celgene will also provide $25 million in funding to bluebird.

What does Wall Street think of the new deal? Here’s a breakdown of what four firms had to say following the announcement.

Wedbush

Wedbush remains bullish on bluebird following the announcement, and expects the anti-BCMA collaboration to focus on multiple myeloma (MM).

“BCMA is primarily expressed by plasma cells, with near universal expression in MM cells. Critically, with regards to preventing off-target toxicities, BCMA does not appear to be expressed in essential normal tissues,” analysts explain.

Wedbush maintains its Outperform rating and $222 price target for bluebird.

Bank of America

Bank of America analysts seem…

Read the rest of this article (and all my other articles) for free on Benzinga by clicking here

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!